Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01237327 | Multicenter Follow Up Study Of Subjects Who Participated In An Original Protocol Of Exemestane Vs. Megestrol Acetate In Postmenopausal Women With Metastatic Breast Cancer | PHASE3 | COMPLETED | 84 | — | — | Nov 1, 2001 | Dec 1, 2009 | May 6, 2011 | 7 | China |
Overall survival in months measured from date of starting treatment in core study to date of death for any reason.
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | - |
| 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Megestrol acetate | DRUG | Megestrol Acetate 160 mg oral tablets Qd |
| exemestane (Aromasin) | DRUG | exemestane (Aromasin) 25 mg oral tablets Qd |
Inclusion Criteria: * Previous participation in study 971-ONC-0028-080. Exclusion Criteria: * Subjects who had not previously participated in study 971-ONC-0028-080.